Anaemia and iron deficiency in chronic heart failure patients
Authors:
Open Access
- 24 May 2019
- journal article
- review article
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 59 (4S) , 4-20
Abstract
Tis review focused on prevalence of anemia and iron defciency (ID) in CHF and their effect on the course and prognosis of this condition. Based on evaluation of numerous laboratory data defnitions of anemia and ID were suggested. Specifcally, a diagnostic value of measuring serum iron, serum ferritin, transferrin saturation, total iron-binding capacity, and concentration of soluble transferrin receptors was discussed. Te review highlighted the importance of measuring bone marrow iron, which is rarely used in everyday clinical practice even though this test is considered a «gold standard» of ID diagnosis. Te review provided an insight into pathogenetic mechanisms of ID in CHF including insufcient iron supply, role of inflammation, erythropoietin, RAS, and effects of some pharmacological therapies. Te authors described physiological consequences of ID and anemia, activation of hemodynamic and non-hemodynamic compensatory mechanisms, which develop in response to anemia and not infrequently aggravate CHF. Special atention was paid to current approaches to treatment of anemia and ID in CHF, including a discussion of efcacy and safety of oral and intravenous dosage forms of iron and hemopoiesis stimulators.Keywords
This publication has 103 references indexed in Scilit:
- Forecasting the Impact of Heart Failure in the United StatesCirculation: Heart Failure, 2013
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart FailureNew England Journal of Medicine, 2013
- Iron Deficiency in Community-Dwelling US Adults With Self-Reported Heart Failure in the National Health and Nutrition Examination Survey IIICirculation: Heart Failure, 2011
- Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trialsAmerican Heart Journal, 2011
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- The Role of Hepcidin in Iron MetabolismActa Haematologica, 2009
- Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndromeAmerican Heart Journal, 2007
- The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMETEuropean Heart Journal, 2006
- Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart FailureCirculation, 2005
- Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failureEuropean Heart Journal, 2005